Efficacy and safety of trifluridine/tipiracil in third-line and beyond for the treatment of patients with metastatic colorectal cancer in routine clinical practice: patterns of use and prognostic nomogram

Ana Fernández Montes; Francisca Vázquez Rivera; Nieves Martínez Lago; M. Covela; A. Cousillas Castiñeiras; Paula González Villarroel; Juan de la Cámara Gómez; J. C. Méndez Méndez; Mercedes Salgado Fernández; Sonia Candamio Folgar; Margarita Reboredo López; Marta Carmona Campos; Elena Gallardo Martín; Mónica Jorge Fernández; Mari Luz Pellón Augusto; L. París Bouzas; Jesús García Gómez

Ayuda

Efficacy and safety of trifluridine/tipiracil in third-line and beyond for the treatment of patients with metastatic colorectal cancer in routine clinical practice: patterns of use and prognostic nomogram

A. Fernandez Montes ^[4] ; F. Vazquez Rivera ^[5] ; N. Martinez Lago ^[1] ; M. Covela Rúa ^[2] ; A. Cousillas Castiñeiras ^[6] ; P. Gonzalez Villarroel ^[3] ; J. de la Cámara Gómez ^[7] ; J. C. Méndez Méndez ^[8] ; M. Salgado Fernández ^[4] ; S. Candamio Folgar ^[5] ; M. Reboredo López ^[1] ; M. Carmona Campos ^[2] ; E. Gallardo Martín ^[6] ; M. Jorge Fernández ^[3] ; M. L. Pellón Augusto ^[7] ; L. París Bouzas ^[8] ; J. García Gómez ^[4]
1. [1] Complexo Hospitalario Universitario da Coruña
  
  Complexo Hospitalario Universitario da Coruña
  
  A Coruña, España
2. [2] Hospital Universitario Lucus Augusti
  
  Hospital Universitario Lucus Augusti
  
  Lugo, España
3. [3] Hospital Álvaro Cunqueiro
  
  Hospital Álvaro Cunqueiro
  
  Vigo, España
4. [4] Complexo Hospitalario Universitario de Ourense
5. [5] Hospital Clínico Universitario de Santiago de Compostela
6. [6] Hospital Provincial de Pontevedra
7. [7] Complexo Hospitalario Universitario Arquitecto Marcide
8. [8] Centro Oncológico de Galicia
Mostrar afiliaciones +
Localización: Clinical & translational oncology, ISSN 1699-048X, Vol. 22, Nº. 3 (March), 2020, págs. 351-359
Idioma: inglés
Texto completo no disponible (Saber más ...)
Resumen
- Introduction Trifluridine/tipiracil combination has shown a benefit over placebo in the treatment of patients with chemorefractory metastatic colorectal cancer (mCRC). We evaluated the efficacy and safety of this combination in the real-life setting at eight Galician centers in Spain.
  
  Patients and methods This is a retrospective study of a cohort of patients with mCRC in treatment with trifluridine/tipiracil within usual clinical practice who have been previously treated or are not considered candidates for treatment with available therapies.
  
  Results A total of 160 mCRC patients were included. Our data showed that 11.9% of patients achieved disease control. Median progression-free survival was 2.75 months; at 5.66 months follow-up, median overall survival was 7.94 months. Asthenia and neutropenia (48.1% both) were the most frequent adverse events. Overall survival was lower in patients with ECOG 2, multiple metastatic sites, platelets count 350,000/µl, alkaline phosphatase > 500 IU/l, and carcinoembryonic antigen > 10 ng/ml.
  
  Conclusion The results of this study confirm the efficacy and safety of trifluridine/tipiracil in chemorefractory mCRC patients. However, patients in clinical practice differ from patients in clinical trials. Due to this, prognostic factors have special importance to offer the best therapeutic approach.